13 November, 2018
Kista, November 13, 2018. Toutatis AB (“Toutatis”) extends operations in its franchise agreement with Chordate Medical AB (“Chordate”), the subsidiary of Chordate Medical Holding AB (publ). On the fourth of December, Toutatis opens a K.O.S-clinic in Gothenburg, which offers private-paying patients Chordate’s treatment for non-allergic rhinitis (“nasal congestion”).
“As we have previously communicated, we will continue to process the Swedish market with our B2C model. It is gratifying that, within the framework of our franchise agreement, we can note that Toutatis is expanding its operations with a clinic in Gothenburg, which is already receiving bookings for the start of December 4th. We will continue to increase our presence in Sweden by adding additional franchise clinics to our B2C concept” says Anders Weilandt, CEO of Chordate.
For more information, please contact:Anders Weilandt, CEOanders.weilandt@chordate.comPhone: +46 (0) 733 87 42 77
Information:The information was provided, through the contact of the above contact person,for publication on November 13, 2018 at. 08:30 CET.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
Press releases
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
The information is handled according to our privacy policy.
This website uses cookies to give you the best and most relevant user experience. Using this website means you consent to the use of cookies. Find out more about cookies on our website.